Provision of Haemodialysis and Plasma Pheresis In Centre Equipment and Associated Consumables

The NHS Wales Shared Services Partnership, hosted by Velindre NHS Trust are acting on behalf of Cardiff and Vale University Local Health Board who sought to to establish a contract for the provision of Haemodialysis and Plasma Pheresis In Centre Equipment and Associated Consumables.

The Nephrology and Transplant Directorate at the University Hospital of Wales (UHW) serves a population of approximately 1.4 million people in South East Wales, providing a complete range of diagnostic and therapeutic services including dialysis and transplantation to adult patients. Our take-on rate for Renal Replacement Therapy (RRT) has recently been approximately 120 patients per million per annum, and approximately 700 patients receive a dialysis therapy at any one time. Our program emphasises the benefits of home therapies, and currently there are approximately 35 patients receiving home haemodialysis with a further 60 on peritoneal therapies.

Outpatient Haemodialysis is delivered through a network of Satellite units across the region, supported by The David Thomas Haemodialysis Unit (DTU) on-site at UHW. DTU has recently been extensively refurbished and has seven stations, providing capacity for up to 28 patients per week. The unit focuses on providing outpatient dialysis for patients with complex needs who require specific care best provided on a Hospital site, and also treats Chronic Haemodialysis patients who may be admitted to UHW with non-renal problems.

Inpatient dialysis is provided to the Directorate’s patients on a 27 bedded Nephrology ward (Ward B5), and on the 20-bedded Cardiff Transplant Unit (CTU) at UHW. Therapies are provided to Chronic Haemodialysis patients, patients with Acute Kidney Injury, and patients in the pre-and post-transplant settings. Plasma exchange is provided where clinically indicated in the management of acute vasculitides, and plasmapheresis may be provided as part of the ABO Incompatible Transplant program as well as in the management of Acute Graft Rejection.

The contract is for a five year period with two years extension option.